* Bioventus Inc BVS.OQ BVS.O is expected to show a rise
in
quarterly revenue when it reports results on November 8.
* The Durham North Carolina-based company is expected to
report
a 30.0% increase in revenue to $141.592 million from $108.89
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Bioventus Inc is
for
earnings of 12 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioventus
Inc is
$15.5, above its last closing price of $7.17.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 0.15 0.16 0.10 Missed -35.9
Mar. 31 2022 0.05 0.05 0.04 Missed -16.7
Dec. 31 2021 0.17 0.18 0.26 Beat 46.5
Sep. 30 2021 0.14 0.14 0.25 Beat 78.6
Jun. 0.10 0.14 0.16 Beat 16.4
30 2021
Mar. 31 2021 0.10 0.10 0.15 Beat 57.9
Dec. 31 2020 0.23 0.23 2.32 Beat 908.7
This summary was machine generated November 4 at 19:31 GMT. All
figures in US dollars unless otherwise stated